Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
67.2 EUR | 0.00% | +1.33% | +97.65% |
Mar. 22 | MorphoSys Gets US Antitrust Approval for Proposed Acquisition by Novartis | MT |
Mar. 22 | Novartis' EUR2.7 Billion Purchase of MorphoSys Secures US Antitrust Clearance | MT |
Sales 2024 * | 252M 271M | Sales 2025 * | 325M 350M | Capitalization | 2.53B 2.72B |
---|---|---|---|---|---|
Net income 2024 * | -182M -196M | Net income 2025 * | -115M -124M | EV / Sales 2024 * | 10.3 x |
Net Debt 2024 * | 59.37M 63.98M | Net cash position 2025 * | 241M 259M | EV / Sales 2025 * | 7.04 x |
P/E ratio 2024 * |
-17.4
x | P/E ratio 2025 * |
-32.6
x | Employees | 524 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.15% |
Latest transcript on MorphoSys AG
1 week | +1.33% | ||
Current month | +3.38% | ||
1 month | +3.19% | ||
3 months | +93.72% | ||
6 months | +154.84% | ||
Current year | +97.65% |
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 19-08-31 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 23-08-06 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 18-05-16 |
Director/Board Member | 67 | 18-05-16 | |
Marc Cluzel
CHM | Chairman | 69 | 12-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.44% | 125 M€ | -.--% | ||
0.80% | 17 M€ | -.--% | - | |
0.11% | 2 M€ | -.--% | ||
0.02% | 735 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 67.2 | 0.00% | 100,985 |
24-03-27 | 67.2 | -0.03% | 84,006 |
24-03-26 | 67.22 | +0.09% | 138,582 |
24-03-25 | 67.16 | -0.03% | 169,514 |
24-03-22 | 67.18 | +1.30% | 399,822 |
Delayed Quote Xetra, March 28, 2024 at 12:40 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+97.65% | 2.73B | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |